Why AstraZeneca plc Beats GlaxoSmithKline plc

AstraZeneca plc (LON: AZN) is beating GlaxoSmithKline plc (LON: GSK) on one key metric.

| More on:

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

When investing, your capital is at risk. The value of your investments can go down as well as up and you may get back less than you put in.

Read More

The content of this article is provided for information purposes only and is not intended to be, nor does it constitute, any form of personal advice. Investments in a currency other than sterling are exposed to currency exchange risk. Currency exchange rates are constantly changing, which may affect the value of the investment in sterling terms. You could lose money in sterling even if the stock price rises in the currency of origin. Stocks listed on overseas exchanges may be subject to additional dealing and exchange rate charges, and may have other tax implications, and may not provide the same, or any, regulatory protection as in the UK.

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More.

Businesses that don’t invest for the future struggle to survive over the long term. And the companies that spend the most on research and development often have the best growth prospects. These companies are able to attract the best talent and investment capital, two traits that will only boost growth prospects. 

In the pharma industry, the research and development of new treatments is essential to growth and AstraZeneca (LSE: AZN) is leading the field in terms of research funding. 

Indeed, during 2014, Astra’s R&D spending as a percentage of sales jumped by a double-digit percentage. The company’s peers, industry behemoths  J&J, Roche, Bayer, SanofiLilly and Pfizer all increased R&D spending by 3% to 5%, in line with sales growth.  

GlaxoSmithKline’s (LSE: GSK) R&D spending as a percentage of sales actually fell by a double-digit percentage as the company struggled to cut costs in an attempt to boost margins. 

Starting to yield results  

Astra’s devotion to R&D spending is really starting to show up in the company’s treatment pipeline and number of drug launches. For example, the company amazed the market last year when it broke records for the number of treatment approved for sale by regulators in the space of twelve months.

However, Astra’s sales are set to continue falling this year as the company grapples with the sliding sales of its blockbuster Crestor drug. But this is expected to be the company’s last year of sales declines.

New treatments are expected to re-ignite sales growth from 2016 onwards and Astra’s management believe that the company can rack up annual sales of $45bn by 2023 — almost double the level reported for 2014. 

Glaxo isn’t following the same path. In fact, Glaxo is transitioning into a consumer goods company as the group focuses on consumer healthcare assets and vaccines.

Granted, these aren’t the most exciting sectors to be involved in, but they are extremely important to the company, and they’re essential to everyday life.

Overall, Glaxo is taking a relatively safe route while Astra chases growth with hefty spending on R&D to try and enhance its treatment pipeline. 

Unfortunately, Astra’s bright prospects mean that investors are willing to pay a premium to get their hands on the company’s shares. Astra currently trades at a forward P/E of 16.6, which may seem expensive to some but it’s a premium worth paying for the company’s long-term growth prospects.

Difficult to choose

It’s almost impossible to choose between Astra and Glaxo. The two pharma giants each have their own strengths and weaknesses.

As Astra chases growth, Glaxo is becoming more defensive and the company’s dividend yield, which currently stands at 5%, is hard to pass up.

Should you invest, the value of your investment may rise or fall and your capital is at risk. Before investing, your individual circumstances should be assessed. Consider taking independent financial advice.

Rupert Hargreaves owns shares of GlaxoSmithKline. The Motley Fool UK has recommended GlaxoSmithKline. We Fools don't all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors.

More on Investing Articles

Petrochemical engineer working at night with digital tablet inside oil and gas refinery plant
Investing Articles

Can the Centrica dividend keep on growing?

Christopher Ruane considers some positive factors that might see continued growth in the Centrica dividend -- as well as some…

Read more »

Smiling family of four enjoying breakfast at sunrise while camping
Investing Articles

How I’d turn my £12,000 of savings into passive income of £1,275 a month

This Fool is considering a strategy that he believes can help him achieve a stable passive income stream with a…

Read more »

Person holding magnifying glass over important document, reading the small print
Investing Articles

2 top FTSE 250 investment trusts trading at attractive discounts!

This pair of discounted FTSE 250 trusts appear to be on sale right now. Here's why I'd scoop up their…

Read more »

Smiling young man sitting in cafe and checking messages, with his laptop in front of him.
Investing Articles

3 things that could push the Lloyds share price to 60p and beyond

The Lloyds share price has broken through 50p. Next step 60p? And then what? Here are some thoughts on what…

Read more »

Young female business analyst looking at a graph chart while working from home
Investing Articles

£1,000 in Rolls-Royce shares a year ago would be worth this much now

Rolls-Royce shares have posted one of the best stock market gains of the past 12 months. But what might the…

Read more »

Investing Articles

Are HSBC shares a FTSE bargain? Here’s what the charts say!

There are plenty of dirt-cheap FTSE 100 banking stocks for investors to choose from today. Our writer Royston Wild believes…

Read more »

Three signposts pointing in different directions, with 'Buy' 'Sell' and 'Hold' on
Investing Articles

Just released: Share Advisor’s latest ‘Hold’ recommendation [PREMIUM PICKS]

In our Share Advisor newsletter service, we provide buy, sell, and hold guidance for our universe of recommendations.

Read more »

Investing Articles

Investing £5 a day could help me build a second income of £329 a month!

This Fool explains how £5 a day, or one less takeaway coffee, could help her build a monthly second income…

Read more »